title: [Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes].
abstract: Oxidized LDL accelerates vascular endothelial damage and the progression of early arteriosclerosis, and is known as an independent risk factor for coronary artery disease. In this study, we administered pioglitazone and pitavastatin for 16 weeks to 18 patients who had type 2 diabetes complicated by dyslipidemia and then investigated the influence of these 2 drugs on MDA-LDL(i. e., oxidized LDL). As a result, a significant decrease of MDA-LDL was observed in both groups, but a significant decrease of the MDA-LDL/LDL-C ratio (an indicator of the extent of oxidation of LDL) was only observed in the pioglitazone group. Accordingly, it was demonstrated that pioglitazone improves oxidative stress, and the possibility was suggested that the MDA-LDL/LDL-C ratio is useful for the evaluation of oxidative stress in clinical practice.
authors.affiliation: Department of Hematology and Endocrinology, Shuto General Hospital.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Taguchi
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Hayashi
mesh_terms: D000368:Aged; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D018450:Disease Progression; D050171:Dyslipidemias / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008077:Lipoproteins, LDL; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D018384:Oxidative Stress; D000077205:Pioglitazone; D011804:Quinolines / Q000008:administration & dosage*; D012307:Risk Factors; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D008077:Lipoproteins, LDL; D011804:Quinolines; D045162:Thiazolidinediones; C099252:oxidized low density lipoprotein; D008315:Malondialdehyde; C108475:pitavastatin; D000077205:Pioglitazone